Treatment with the aldosterone synthase inhibitor lorundrostat significantly decreased automated office systolic blood pressure in adults with uncontrolled hypertension in the phase 2 TARGET-HTN trial.
The investigational siRNA therapeutic showed consistent and sustained reductions in systolic blood pressure in a phase 2 study of adults with hypertension.
The FDA s Circulatory System Devices Panel unanimously agreed that Medtronic s Spyral Renal Denervation device was safe, but the panel was split on its efficacy and whether its benefits outweigh the risks.
The ReCor renal denervation system for treating refractory hypertension is safe and effective but further study is needed in vulnerable subpopulations, an FDA advisory panel concludes.